Anshul Maheshwari Sells 2,439 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 2,439 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the transaction, the chief financial officer now owns 194,623 shares of the company’s stock, valued at $2,467,819.64. The trade was a 1.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, September 3rd, Anshul Maheshwari sold 1,414 shares of SI-BONE stock. The stock was sold at an average price of $16.35, for a total transaction of $23,118.90.

SI-BONE Stock Performance

Shares of SIBN traded down $0.17 during trading hours on Wednesday, hitting $12.15. The stock had a trading volume of 217,144 shares, compared to its average volume of 392,037. SI-BONE, Inc. has a 12 month low of $11.76 and a 12 month high of $21.70. The stock has a fifty day moving average price of $13.91 and a 200 day moving average price of $14.26. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a market capitalization of $509.57 million, a PE ratio of -13.39 and a beta of 1.22.

Analyst Ratings Changes

Several equities research analysts recently commented on SIBN shares. Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of SI-BONE in a research note on Wednesday. Truist Financial raised their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Morgan Stanley dropped their target price on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SI-BONE has an average rating of “Buy” and an average target price of $23.00.

Hedge Funds Weigh In On SI-BONE

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in SI-BONE by 1.8% in the first quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock worth $40,328,000 after buying an additional 43,670 shares in the last quarter. Bessemer Group Inc. raised its position in shares of SI-BONE by 79.8% during the first quarter. Bessemer Group Inc. now owns 37,859 shares of the company’s stock valued at $620,000 after buying an additional 16,800 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of SI-BONE by 7.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock worth $336,000 after buying an additional 1,372 shares in the last quarter. Bellevue Group AG boosted its position in shares of SI-BONE by 810.5% during the first quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock worth $18,661,000 after acquiring an additional 1,014,756 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC grew its stake in SI-BONE by 13.8% during the first quarter. Silvercrest Asset Management Group LLC now owns 1,060,937 shares of the company’s stock valued at $17,368,000 after acquiring an additional 128,702 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.